Merck & Co., Inc. is getting into the well-trodden space of bispecific antibodies by acquiring CN201, a CD19xCD3-directed candidate, from a Chinese biotech company.
The Rahway, NJ-based drug maker said 9 August that it acquired the drug from Curon Biopharmaceutical Limited and plans...